Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Pamplona – page 61

761 clinical trials in Pamplona, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Pamplona at a glance
761
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

761 trials in Pamplona

Open in trial search

Cholangiocarcinoma+3

Not recruiting

Study on the Effects of Volrustomig and Drug Combination for Patients with Advanced Hepatobiliary Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AstraZeneca AB

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Giredestrant or Tamoxifen for Premenopausal Women with Early ER-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Giredestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Non-small cell lung cancer

Not recruiting

Study Comparing DZD9008 and Chemotherapy for First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Dizal Pharmaceutical Co. Ltd.

Hepatocellular carcinoma

Not recruiting

Study of Relatlimab and Nivolumab for Patients with Advanced Liver Cancer Who Have Not Received Immunotherapy After Tyrosine Kinase Inhibitor Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Dementia Alzheimer's type

Not recruiting

Study on the Safety and Effectiveness of MK-1942 for Patients with Mild to Moderate Alzheimer's Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:MK-1942
  • Sponsor:Merck Sharp & Dohme LLC

Dementia Alzheimer's type

Not recruiting

Study on the Effects of ABBV-552 in Patients Aged 50-90 with Mild Alzheimer's Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:(4R)-1-[(5-Chloro-1H-1,2,4-Triazol-1-Yl)Methyl]-4-(3,4,5-Trifluorophenyl)-2-Pyrrolidinone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Ovarian epithelial cancer

Not recruiting

Study of Chemotherapy With Pembrolizumab and Olaparib for Patients With Advanced Epithelial Ovarian Cancer Without BRCA Mutation

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Dry age-related macular degeneration

Not recruiting

Study on JNJ-81201887 for Treating Geographic Atrophy in Age-related Macular Degeneration Patients

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Janssen Cilag International

Polycythaemia vera

Not recruiting

Study of SLN124 for Patients with Polycythemia Vera

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Tmprss6 Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Silence Therapeutics PLC

Endometrial cancer

Not recruiting

Study on GEN1046 and Pembrolizumab for Patients with Advanced Endometrial Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:GEN1046
  • Sponsor:Genmab A/S

Acute coronary syndrome

Not recruiting

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Hepatocellular carcinoma

Not recruiting

Study of Durvalumab and Tremelimumab for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Pamplona

What the registry says about research in the country

01 Oncology Research

Innovative trials exploring treatments for various cancers, including metastatic colorectal cancer, bladder cancer, and prostate cancer. Studies focus on combination therapies and novel treatment approaches.

  • Colorectal Cancer Treatment Studies
  • Prostate Cancer Therapies
  • Blood Cancer Research

Multiple trials evaluating immunotherapies and targeted treatments for improving patient outcomes.

02 Immunology and Inflammation

Research focused on treating autoimmune conditions and inflammatory disorders, including studies on cutaneous lupus erythematosus and atopic dermatitis.

  • Lupus Treatment Studies
  • Dermatological Conditions
  • Immune System Disorders

Evaluating new therapeutic approaches for chronic inflammatory conditions.

03 Respiratory Medicine

Clinical investigations targeting respiratory conditions, including studies on COPD and respiratory viral infections. Research focuses on improving treatment outcomes.

  • COPD Management
  • Respiratory Virus Prevention
  • Nasal Polyps Treatment

Development of innovative therapies for respiratory diseases and infections.

04 Metabolic Disorders

Studies addressing obesity, diabetes, and related metabolic conditions. Research focuses on weight management and blood sugar control.

  • Type 2 Diabetes Treatment
  • Weight Management Therapies
  • Metabolic Disease Research

Investigating new approaches for metabolic disorder management.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.